TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort

Rodríguez Sanz María, Pineda Moncusí Marta, Servitja Sonia, Garcia Giralt Natalia, Martos Tamara, Tusquets Ignasi, Martínez García Maria, Rodriguez Morera Jaime, Diez Perez Adolfo, Albanell Joan, Nogués Xavier

    Research output: Contribution to journalArticleResearchpeer-review

    14 Citations (Scopus)

    Abstract

    © 2016 Introduction Patients with breast cancer under aromatase inhibitor (AI) treatment often develop osteoporosis and their average bone loss rate is twice that of natural reduction during menopause, increasing fracture risk. As the current diagnostic technique based on bone mineral density (BMD) provides no information on bone quality, the Trabecular Bone Score (TBS) has been proposed to reflect bone microarchitecture status. The present study was designed to assess prospective changes in TBS and lumbar spine (LS) BMD in postmenopausal women with breast cancer at completion of AI treatment. Methods B-ABLE is a prospective cohort of 735 women with breast cancer treated with AIs according to American Society of Clinical Oncology recommendations: 5 years of AI starting within 6 weeks post-surgery or 1 month after the last cycle of chemotherapy (5y-AI group), or switching to an AI to complete 5-year therapy after 2–3 years of tamoxifen (pTMX-AI group). Patients with osteoporosis were treated with oral bisphosphonates (BP). TBS and LS-BMD changes at completion of AI therapy were evaluated by Student t-test for paired samples. Pearson correlation coefficients were computed for correlations between LS-BMD and TBS. Results AI treatment was completed by 277 women. Of these, 70 (25.3%) were allocated to BP therapy. The non-BP-treated patients (74.7%) showed significant decreases in TBS (− 2.94% in pTMX-AI and − 2.93% in 5y-AI groups) and in LS-BMD (− 4.14% in pTMX-AI and − 2.28% in 5y-AI groups) at the end of AI treatment. In BP-treated patients, TBS remained stable at the end of AI treatment, whereas LS-BMD showed significant increases (+ 2.30% in pTMX-AI and + 5.33% in 5y-AI groups). Moderate associations between TBS and LS-BMD values at baseline and at the end of AI treatment (r = 0.4; P < 0.001) were observed. At the end of treatment, changes in spine BMD and TBS were weakly correlated (r = 0.1, P < 0.01). Conclusions AI therapy induces significant decreases in TBS, comparable to BMD loss. BP-treated patients maintained TBS values, whereas BMD increased. AI treatment leads to deterioration of bone microarchitecture, which seems to be attenuated by BP therapy.
    Original languageEnglish
    Pages (from-to)1-8
    JournalBone
    Volume92
    DOIs
    Publication statusPublished - 1 Nov 2016

    Keywords

    • Aromatase inhibitors
    • Bone mineral density
    • Breast cancer
    • Oral bisphosphonates
    • Tamoxifen
    • Trabecular Bone Score

    Fingerprint

    Dive into the research topics of 'TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort'. Together they form a unique fingerprint.

    Cite this